Zacks Research Upgrades TG Therapeutics (NASDAQ:TGTX) to Hold

Posted by Brenda Bartman on Oct 8th, 2026

TG Therapeutics (NASDAQ:TGTX – Get Free Report) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Tuesday, Zacks reports.

TGTX has been the subject of several other research reports. Jefferies Financial Group reiterated a “buy” rating and set a $83.00 price objective on shares of TG Therapeutics in a report on Monday, June 22nd. JPMorgan Chase & Co. boosted their target price on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Bank of America upped their target price on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. HC Wainwright reissued a “buy” rating and issued a $78.00 price target on shares of TG Therapeutics in a report on Tuesday, September 1st. Finally, B. Riley Financial boosted their price target on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $63.00.

Get Our Latest Research Report on TGTX

TG Therapeutics Trading Up 1.5%

NASDAQ:TGTX opened at $52.95 on Tuesday. TG Therapeutics has a 52 week low of $26.76 and a 52 week high of $59.30. The firm has a 50 day moving average of $53.61 and a 200 day moving average of $47.07. The company has a quick ratio of 3.72, a current ratio of 4.27 and a debt-to-equity ratio of 1.23. The stock has a market capitalization of $8.11 billion, a price-to-earnings ratio of 19.32, a PEG ratio of 2.24 and a beta of 1.80.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The firm had revenue of $240.34 million during the quarter, compared to analysts’ expectations of $229.77 million. During the same period in the prior year, the firm posted $0.17 earnings per share. TG Therapeutics’s revenue for the quarter was up 70.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that TG Therapeutics will post 0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other news, Director Laurence Charney sold 5,000 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the sale, the director directly owned 168,640 shares of the company’s stock, valued at $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.87% of the stock is owned by company insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in TG Therapeutics during the second quarter valued at $1,211,429,000. Bank of America Corp DE purchased a new position in shares of TG Therapeutics during the 2nd quarter valued at about $71,960,000. Bank of New York Mellon Corp purchased a new position in shares of TG Therapeutics during the 2nd quarter valued at about $49,472,000. Dimensional Fund Advisors LP lifted its holdings in shares of TG Therapeutics by 129.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company’s stock valued at $36,029,000 after buying an additional 612,068 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in shares of TG Therapeutics by 697.6% in the 2nd quarter. Wellington Management Group LLP now owns 478,265 shares of the biopharmaceutical company’s stock valued at $26,276,000 after buying an additional 418,300 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

(Get Free Report)

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell-mediated diseases, including multiple sclerosis and B-cell malignancies. The company’s research and development activities center on antibody-based therapies designed to target B cells and related immune pathways.

TG Therapeutics’ principal marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.